Tocotrienol Supplementation for Aging Markers in Healthy Middle-Aged Adults
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Evaluating Tocotrienol-Rich Fraction as a Senolytic Agent in Middle-Aged Adults
Run by National University of Malaysia · NCT07637487 · Data updated 2026-11-12
Healthy adults aged 35–64 will take either tocotrienol or a placebo for 6 months to see if it can reduce cellular aging markers and improve health signals.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 35 Years to 50 Years |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | National University of Malaysia Academic / other |
| Locations | 1 site (Kuala Lumpur, Kuala Lumpur) |
| Status | Recruiting |
| Started | October 31, 2023 |
| Main results expected | December 19, 2024 |
| Study ends | January 30, 2027 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT07637487 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 35–64 who are generally healthy by medical examination and not taking vitamin E supplements or palm oil–based products in the prior 3 months.
✕Probably not a fit
Individuals with chronic heart or related conditions, fat malabsorption, or significant liver or kidney dysfunction may not benefit and could be at risk.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study tests whether daily tocotrienol (200 mg) can influence aging-related biological pathways in otherwise healthy middle-aged adults. Participants will be randomized to receive either tocotrienol or a placebo for six months, with visits at baseline, 3 months, and 6 months for clinical assessments and laboratory testing. Outcomes include senescence-associated markers, inflammation, oxidative stress, and mitochondrial function, along with safety evaluations. The study compares a tocotrienol-rich fraction against placebo to determine potential effects on aging biomarkers and related health changes.
Why it matters
Potential benefit: If successful, tocotrienol could help modulate aging-related biological processes and potentially improve health markers in middle-aged adults.
How similar studies have gone: Previous research on senolytic approaches and vitamin E analogs suggests aging-biomarker effects are possible, but results are mixed and this appears to be a novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Generally healthy as assessed by physical examination and blood lab test, including adequate liver and renal function, Neutrophil count \> 1500/mm3, Platelet count 120,000 - 450,000/mm3, Haemoglobin concentration 11.5 to 19.0g/dL for men; 10.5-17.5 g/dL for women, Prothrombin and partial thromboplastin time within normal range, ALT and AST \< 80 IU/L, Creatinine 0.7 to 1.3 mg/dL * Subject of either gender, 35 to 64 years of age (inclusive) * Not allergy to palm oil and vitamin E * Do not take vitamin E supplements over the past 3 months * Provide written informed consent prior to screening * Subject is willing and able to comply with the study visit schedule and procedure, geographic proximity (investigator's discretion) that allows adequate follow up * Subjects understand the study protocol and signed informed consent forms Exclusion Criteria: * Subjects with fat malabsorption * Subjects with chronic conditions such as cardiac diseases (heart failure, myocardial infraction, ischemic heart disease), neurological diseases, diabetes, HIV infection, psychiatric illness/social situations * Subjects with vegan diet * Current smoker or used to smoke in the past 3 months * Subject for surgery or had undergone surgery in the past 3 months * Current or past history of drug, alcohol abuse and cancer * Pregnant and lactating women * History of bleeding tendencies or any condition predisposing to bleeding e.g. thrombocytopenia, abnormal liver function, liver disease (e.g. chronic hepatitis), gastrointestinal ulcers * Any subject taking antibiotics or other medication or dietary supplement which could interfere with the action of tocotrienols * Subjects who are pre-disposed to inherited blood/circulation disorders * Subject who is taking anticoagulants and antithrombotic drugs, e.g. warfarin, aspirin, ticlopidine, heparin, etc.
Where it's running
-
National University of Malaysia
Kuala Lumpur, Kuala Lumpur, Malaysia Recruiting
Study contacts
- Study coordinator: Suzana Makpol
- Email: suzanamakpol@ukm.edu.my
- Phone: 603-91459554
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.